Question 1

What is AMIVANTAMAB-VMJW used for?

Accepted Answer

AMIVANTAMAB-VMJW (brand name Rybrevant) is a Other indicated for as detected by an FDA-approved test. ( 1, 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1.

Question 2

How does AMIVANTAMAB-VMJW work?

Accepted Answer

AMIVANTAMAB-VMJW works through the following mechanism: 12.1 Mechanism of Action Amivantamab-vmjw is a bispecific antibody that binds to the extracellular domains of EGFR and MET. In in vitro and in vivo studies amivantamab-vmjw was able to disrupt EGFR and MET signaling functions in mutation models of exon 19 deletions, exon 21 L858R substitutions, and exon 20 insertions through blocking ligand binding or degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively. Treatment with amivantamab in combination with lazertinib increased in vivo anti-tumor activity compared to either agent alone in a mouse xenograft model of human NSCLC with an EGFR L858R mutation..

Question 3

What are the most common side effects of AMIVANTAMAB-VMJW?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for AMIVANTAMAB-VMJW. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is AMIVANTAMAB-VMJW the same as Rybrevant?

Accepted Answer

Rybrevant is a brand name for AMIVANTAMAB-VMJW. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

AMIVANTAMAB-VMJW

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations